EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC

View source ↗

Summary

EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The application covered indicatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Macular Edema
• Retinal Vein Occlusion
• Wet Age-related Macular Degeneration

Drugs mentioned

• Skojoy (aflibercept)

Snippet

Status: Application withdrawn. Therapeutic area: Wet Macular Degeneration;Macular Edema;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Amgen Technology (Ireland) UC. Decision date: 30/01/2025